UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of Each ClassTicker SymbolName of Exchange on Which Registered Common Stock, par value $0.001 per share CPRX NASDAQ Capital Market Emerging growth company ☐ FORM 10-Q [Mark One] ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2020 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-33057 CAT ...

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q1 2020 Earnings Conference Call May 12, 2020 8:30 AM ET Company Participants Alicia Grande - Chief Financial Officer Patrick McEnany - Chairman and Chief Executive Officer Dan Brennan - Chief Commercial Officer Steven Miller - Chief Operating Officer and Chief Scientific Officer Conference Call Participants Joe Catanzaro - Piper Sandler Charles Duncan - Cantor Fitzgerald Leland Gershell - Oppenheimer Scott Henry - ROTH Capital Operator Greetings and welcome to ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [Mark One] ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2020 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-33057 355 Alhambra Circle Suite 1250 Coral Gables, Florida 33134 (Address of principal executive offices) (Zip Code) (IRS Employer Identification No.) Re ...

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q4 2019 Earnings Conference Call March 17, 2020 8:30 AM ET Company Participants Alicia Grande - Chief Financial Officer Patrick McEnany - Chairman and Chief Executive Officer Daniel Brennan - Chief Commercial Officer Steven Miller - Chief Operating Officer and Chief Scientific Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald & Co. Joseph Catanzaro - Piper Sandler Leland Gershell - Oppenheimer & Co. Inc. Scott Henry - ROTH Capital Partners, ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [Mark One] ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-33057 CATALYST PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 76-0837053 (State of jurisdiction of incorporation ...

| --- | --- | --- | --- | --- | --- | --- | --- | |-------|--------------|-------|-------|-----------------------------------------------------------------------|-------|-------|-----------------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Catalyst Corporate Presentation San Francisco, CA January 13-16, 2020 | | | Pharmaceuticals | | | | | | | | | | | | Confidential | | | | | | | Safe Harbor 2 Confidential This presentation contains forward-looking statements that are subject to a numbe ...

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q3 2019 Results Earnings Conference Call November 13, 2019 8:30 AM ET Company Participants Alicia Grande - Chief Financial Officer Patrick McEnany - Chairman and Chief Executive Officer Steve Miller - Chief Operating Officer and Chief Scientific Officer Dan Brennan - Chief Commercial Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Joe Catanzaro - Piper Jaffray Leland Gershell - Oppenheimer Scott Henry - ROTH Capital Operator Greetings. Wel ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [Mark One] ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2019 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-33057 | --- | --- | |-------------------------------------------------------------------------------------------------------|------------------------ ...

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q2 2019 Earnings Conference Call August 8, 2019 8:30 AM ET Company Participants Alicia Grande - Chief Financial Officer Pat McEnany - Chairman and Chief Executive Officer Dan Brennan - Chief Commercial Officer Steve Miller - Chief Operating Officer and Chief Scientific Officer Gary Ingenito - Chief Medical Officer and Head of Regulatory Affairs Conference Call Participants Charles Duncan - Cantor Fitzgerald Joe Catanzaro - Piper Jaffray Leland Gershell - Oppenhei ...

Table of Contents Title of Each ClassTicker Symbol(s)Name of Exchange on Which Registered Common Stock, par value $0.001 per share CPRX NASDAQ Capital Market Large accelerated filer ☐ Accelerated Filer ☒ Non-accelerated filer ☐ Smaller reporting company ☒ Emerging growth company ☐ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [Mark One] ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2019 OR ...